Transaction DateRecipientSharesTypePriceValue
16th February 2021Thomas Gad4,000Open or private sale$47.09$188,366.80
16th February 2021Thomas Gad7,000Open or private sale$47.08$329,555.80
16th February 2021Thomas Gad7,000Exercise of derivative$2.00$14,000.00
9th February 2021James Healy450,000Open or private purchase$20.00$9,000,000.00
9th February 2021James Healy1,200,228Conversion of derivative$0.00
9th February 2021James Healy1,104,209Conversion of derivative$0.00
19th January 2021David N Gill2,000Exercise of derivative$11.16$22,320.00
19th January 2021Thomas Gad7,000Exercise of derivative$2.00$14,000.00
19th January 2021David N Gill2,000Open or private sale$46.52$93,045.20
19th January 2021Thomas Gad4,000Open or private sale$46.56$186,230.40
Y M Abs Therapeutics
Y M Abs Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.


Y-mAbs Therapeutics is a clinical-stage biopharmaceutical company. It develops novel antibody therapeutics for oncology targets. The company's services include discovery, protein engineering, clinical and regulatory.


Ticker: YMAB
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1722964
Employees: 32
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $158 M (0%)
Other Assets, Current: $5 M (9%)
Assets, Current: $163 M (-22%)
Property, Plant and Equipment, Net: $2 M (-7%)
Other Assets, Noncurrent: $357 Th (-3%)
Assets: $167 M (-22%)
Accounts Payable, Current: $10 M (15%)
Accrued Liabilities, Current: $5 M (0%)
Liabilities, Current: $16 M (15%)
Other Liabilities, Noncurrent: $2 M (614%)
Liabilities: $21 M (22%)
Common Stock, Value, Issued: $4 Th (0%)
Common Stock, Shares, Issued: $40 M (0%)
Retained Earnings (Accumulated Deficit): $232 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $16 Th (-68%)
Stockholders' Equity (Parent): $146 M (0%)
Liabilities and Equity: $167 M (-22%)
Research and Development: $30 M (-38%)
General and Administrative Expenses: $10 M (-43%)
Operating Income/Loss: $40 M (-39%)